Bronchiolitis primary prevention: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 12: Line 12:


[[Category:Needs content]]
[[Category:Needs content]]
[[Category:Viral diseases]]
[[Category:Viral diseases]]
[[Category:Inflammations]]
[[Category:Inflammations]]
Line 17: Line 18:
[[Category:Pulmonology]]
[[Category:Pulmonology]]
[[Category:Disease]]
[[Category:Disease]]
[[Category:primary care]]
[[Category:Emergency medicine]]




{{WH}}
{{WH}}
{{WS}}
{{WS}}

Revision as of 19:49, 4 March 2013

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Bronchiolitis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Bronchiolitis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Severity Score

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

X Ray

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Bronchiolitis primary prevention On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Bronchiolitis primary prevention

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Bronchiolitis primary prevention

CDC on Bronchiolitis primary prevention

Bronchiolitis primary prevention in the news

Blogs on Bronchiolitis primary prevention

Directions to Hospitals Treating Bronchiolitis

Risk calculators and risk factors for Bronchiolitis primary prevention

Overview

In general, prevention of bronchiolitis relies on measures to reduce the spread of the viruses that cause respiratory infections (that is, handwashing, and avoiding exposure to those symptomatic with respiratory infections).

Premature infants, and others with certain majory cardiac and respiratory disorders, can receive passive immunization with Palivizumab (a monoclonal antibody against RSV). This form of passive immunization therapy requires monthly injections every winter. Whether it could benefit infants with lung problems secondary to muscular dystrophies and other vulnerable groups is currently unknown.

References


Template:WH Template:WS